IDH2 and central nervous system cancer: Among all gliomas with IDH mutations, patients with IDH mutations in the I-X group had a shorter median survival (28 months) than patients with I-A tumors (51 months, P = 0.007) or I-CF tumors (96 months, P <0.001) (Figure 4).